Posted on January 22, 20241/22/24
EVERSANA’s High-Quality HEOR Methods Recognized in Published Independent Review
Posted on January 15, 20241/15/24
HemGenix Shines in Collaborative ITC Analysis: EVERSANA and CSL Behring Propel Gene Therapy to the Forefront in Hemophilia B Treatment
Posted on August 25, 20238/25/23
Unlocking Global Success: The Crucial Role of Integrated HEOR Programs in New Product Launches
Posted on May 16, 20235/16/23
Critical Success Factors for Launching Products with Fast Track, PRIME, or ILAP Designation
Posted on April 17, 20234/17/23
What EVERSANA’s Growing Abstract Count at ISPOR U.S. Means to the HEOR Industry
Posted on March 1, 20233/1/23
Filling the Missing Spaces in Your Network Meta-Analysis: The Role of Surrogate Models
Posted on February 27, 20232/27/23
Single-Arm Data: Turning Limitations into Strengths with Numbers
Posted on February 27, 20232/27/23
Eight Key Strategic Considerations When Launching a Global Indirect Treatment Comparison Program for New Products
Posted on February 8, 20232/8/23